

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number  
**WO 01/22093 A1**

(51) International Patent Classification<sup>7</sup>: **G01N 33/68**,  
A61K 38/29, A61P 19/10, C12Q 1/42

(US). SATTERWHITE, Julie [US/US]; 10465 Fox Trace,  
Zionsville, IN 46077 (US).

(21) International Application Number: PCT/US00/24745

(74) Common Representative: **ELI LILLY AND COM-  
PANY**; Lilly Corporate Center, Drop Code 1104, Indi-  
anapolis, IN 46285 (US).

(22) International Filing Date:  
11 September 2000 (11.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/154,879 20 September 1999 (20.09.1999) US  
60/156,803 30 September 1999 (30.09.1999) US  
60/196,370 12 April 2000 (12.04.2000) US

(71) Applicant (for all designated States except US): **ELI  
LILLY AND COMPANY** [US/US]; Lilly Corporate  
Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HOCK, Janet, M.**  
[US/US]; 7702 Candlewood Lane, Indianapolis, IN 46250


(81) Designated States (national): AE, AG, AL, AM, AT, AT  
(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility  
model), DK, DK (utility model), DM, DZ, EE, EE (utility  
model), ES, FI, FI (utility model), GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility  
model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,  
MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT,  
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: METHOD FOR MONITORING TREATMENT WITH A PARATHYROID HORMONE

Procollagen Peptide I  
Median Percent Change  $\pm$  SE  
GHAJ - All Randomly Assigned Patients



(57) Abstract: The present invention relates to a method for monitoring effects of administration of a parathyroid hormone by determining levels of one or more markers of an activity of this hormone. Suitable markers of bone formation include one or more enzymes indicative of osteoblastic processes of bone formation, preferably bone specific alkaline phosphatase, and/or one or more products of collagen biosynthesis, preferably a procollagen I C-terminal propetide. Suitable markers of bone resorption and turnover include one or more products of collagen degradation, preferably an N-terminal telopeptide (NTX). In addition, methods for concurrently reducing the risk of both vertebral and non-vertebral bone fracture in a male human subject at risk of or having osteoporosis are also disclosed, involving administration of human parathyroid hormone (amino acid sequence 1-34) without concurrent administration of an antiseropositive agent other than vitamin D or calcium.

SCANNED, # 24

WO 01/22093 A1